OJSC VEROPHARM ANNOUNCES PRELIMINARY RESULTS FOR THE FIRST HALF OF 2011 YEAR

Transcription

1 PRESS-RELEASE FOR IMMEDIATE DISTRIBUTION 23 TH AUGUST 2011 OJSC VEROPHARM ANNOUNCES PRELIMINARY RESULTS FOR THE FIRST HALF OF 2011 YEAR AUGUST 23, 2011, MOSCOW OJSC «VEROPHARM» [RTS:VRPH, MICEX:VFRM] annunces preliminary data and peratinal perfrmance indicatrs fr the first half f 2011 year accrding t the management accunting. SALES - In H sales f Verpharm s finished gds increased by 18% cmpared t the same perid in 2010, reaching RUR 3,154.8 millin. [1] Rx drugs sales amunted t RUR 2,189.4 millin in H1 2011, a 16,4% inecrease in cmparisn with H The Rx drugs sales accunted fr 69,4% f ttal finished gds sales. [2] OTC drugs sales amunted t RUR millin in H1 2011, a 32,2% increase in cmparisn with H The share f OTC drugs sales accunted fr 12,5% f ttal finished gds sales. In H traditinal drug sales amunted t RUR 13.7 millin, which represents 55,1% decrease as cmpared t H1 2010, and made up 0,4% f ttal finished gds sales. Grup f nn-pharmaceutical prducts Adhesive bandages and csmetic prducts sales came t RUR millin, a 20,3% increase in cmparisn with H The share f adhesive bandages and csmetic prducts in ttal finished gds sales f the Cmpany was 17,7%. Verpharm sales as part f the Federal Reimbursement Prgram (FRP) came t RUR 79,1 millin, accunting fr 2,5% f the Cmpany s ttal finished gds sales. [2] In H sales in Russian Federatin prvide 97% f the Сmpany's sales. In H exprts accunted fr 3% f the Cmpany s ttal finished gds sales cmpared t 2% in H , Mscw, Russia, Barabanniy per., 3, tel.: (+7495)

2 RX drugs segment Ttal sales f the five mst ppular prescriptin drugs by the results in H amunted t RUR millin, r 36% f sales in the prescriptin drugs segment and 25% f the Cmpany s ttal finished gds sales [2]. The five tp-selling Rx drugs in H results include: Irunine (Itracnazle; ATC [3] «General anti-infectives systemic»); sales grwth in cmparisn with H amunted 98%; 10% f sales in the prescriptin drugs Cerepr (Hlina Alfstserat; ATC «Central nervus system»); sales grwth in cmparisn with H amunted 42%; 9% f sales in the prescriptin drugs Geptr (Ademetinine; ATC«Digestive tract and metablism»); sales grwth in cmparisn with H amunted 57%; 7% f sales in the prescriptin drugs Amigrenin (Sumatriptan; ATC «Central nervus system»); sales grwth in cmparisn with H amunted 138%; 5% f sales in the prescriptin drugs Paclitaxel-LENS (Paclitaxel; ATC «Antineplastic and immunmdulating agents»); sales grwth in cmparisn with H amunted 8%; 5% f sales in the prescriptin drugs OTC drugs segment Ttal sales f the five prducts in the OTC drugs segment amunted t 99% f sales in the OTC drugs segment. Xilen (Xylmetazline; ATC «Respiratry system»); sales grwth in cmparisn with H amunted 35%; 49% f sales in the OTC drugs Slabilen (Sdium picsulfate; ATC «Alimentary tract and metablism»); sales grwth in cmparisn with H amunted 34%; 30% f sales in the OTC drugs Mtilak (Dmperidne; ATC «Alimentary tract and metablism»); sales grwth in cmparisn with H amunted 18%; 15% f sales in the OTC drugs Vitasharm and Vitatress (ATC «Vitamins»); sales grwth in cmparisn with H amunted 271%; 4% f sales in the OTC drugs Ginectex vaginal tablets (Benzalknium chlride; ATC «Urinary system&sex hrmne»); 1% f sales in the OTC drugs segment , Mscw, Russia, Barabanniy per., 3, tel.: (+7495)

3 Traditinal drugs segment Ttal sales f the five mst ppular traditinal drugs by the results in H amunted t RUR 13,4 millin, r 97% f sales in the traditinal drugs segment. Ver-Dexamethasne (Dexamethasne; ATC «Hrmnal drugs»); 57% f sales in the traditinal drugs Pyridxine hydrchlride (Pyridxine; ATC «Alimentary tract and metablism»); 24% f sales in the traditinal drugs Flucnazle (Flucnazle; ATC «General anti-infective systemic»); 11% f sales in the traditinal drugs Ver-Ciprflxacin (Ciprflxacin; ATC «General anti-infective systemic»); 3% f sales in the traditinal drugs Ver-Lperamide (Lperamide; ATC «Alimentary tract and metablism»); 2% f sales in the traditinal drugs segment. Adhesive bandages and csmetic prducts segment In H segment f Adhesive bandages and Csmetic prducts had the fllwing structure: Cnventinal bacterial adhesive bandages; 46% f sales in segment in H1 2011; Cnventinal reel adhesive bandages; 25% f sales in the segment in H1 2011; Therapeutic patches - pepper plasters, 12% f sales in the segment in H1 2011; Therapeutic patches - crn plasters, 16% f sales in the segment in H1 2011; Csmetic prducts (Vermistin Silver, Daily, Flres); 1% f sales in the segment in H NEW DRUGS PRODUCTION AND SALES During the first half f 2011 Verpharm launched prductin and sales f the fllwing new drugs: Ver-Netilmicin (Netilmicin; ATC «Antiinfectives fr systemic use»); Ver-Asparaginase (Asparaginase; АТС «Antineplastic and immunmdulating agents»); new dsage ME 10; Verklast (Zledrnic acid; ATC «Musculskeletal system»); new dsage 4mg/5 ml 5ml 1; Vermistin Silver (Myramistin; Remedy fr intimate hygiene); new dsage 50ml 1; Vermistin Daily (Myramistin; Remedy fr hygienic treatment f the skin f hands and feet); new dsage 50ml 1; Vermistin Flres (Myramistin; Remedy fr ral hygiene); new dsage 50ml , Mscw, Russia, Barabanniy per., 3, tel.: (+7495)

4 NEW DRUGS REGISTRATION In the first half f 2011 received registratin certificate fr the fllwing prducts: - The bandage Uniplast intment; - The bandage Uniplast wund srbent; Additinally, 14 drugs are currently at different stages f the registratin prcess. DEBT At the end f 1H 2011 Verpharm s debt came t RUR millin, that represents less than 20% f net assets. [1] [2] [3] accrding t management accunts f OJSC Verpharm % - percent f finished gds sales ATC anatmic-therapeutic-chemical grup Fr further infrmatin please call OJSC Verpharm : Maksutva Nadiya, Chief Financial Officer maksutva.nadiya@verpharm.ru tel. (+7495) Or web-site f the Cmpany , Mscw, Russia, Barabanniy per., 3, tel.: (+7495)

5 Ntes t the Editr: VEROPHARM is ne f the largest Russian pharmaceutical prducers. Shares f the Cmpany are listed n RTS (ticker: VRPH) and are als traded at MICEX (ticker: VFRM). Market capitalizatin as f July 1, 2011 ttaled $449.1 millin (accrding t RTS). The charter capital f the Cmpany ttals 10 millin rdinary shares. VEROPHARM is the market leader in Russia fr prductin f plasters and nclgical medicines. The Cmpany s prductin facilities cmprise 3 pharmaceutical plants in Belgrd, Vrnezh and Pkrv. The Cmpany s prduct prtfli includes mre than 300 items. VEROPHARM emplys mre then 2,000 peple. In the annual study cnducted by the prtal SuperJb.ru amng 290,000 Russian cmpanies VEROPHARM recgnized as ne f the mst attractive emplyers in the labr market and becme "Attractive emplyer Accrding t IMS Health as f the first half f 2011 Verpharm ranked 4 th amng Russian pharmaceutical prducers in prductin vlume terms (mved frm 5th as cmpared t 1H2010 results). Accrding t IMS Health, as f the first half f 2011 cmpared t 2010 Verpharm ranked 6th psitin in verall ranking f nclgy drugs prducers. As far as nclgy drug prducers ranking in pack terms cncerned, Verpharm maintained its leading psitin. THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS TO PURCHASE, ANY SECURITIES IN THE RUSSIAN FEDERATION. NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. This dcument may include statements that are frward-lking statements, including future perating results f the Cmpany. These frward-lking statements invlve risk and uncertainty regarding implementatin f future activities. As a result, actual future results may differ materially frm the plans, gals and expectatins set ut in these frward-lking statements. The Cmpany undertakes n bligatin t change these statements t reflect actual results. This dcument des nt cntain a public ffer t purchase securities in the US. The securities referred t herein have nt been and will nt be registered under the US Securities Act f 1933, as amended (the "Securities Act"), and may nt be ffered r sld in the United States r t US persns. This cmmunicatin is being distributed nly t and is directed nly at (a) persns utside the United Kingdm, (b) persns wh have prfessinal experience in matters relating t investments, i.e., investment prfessinals within the meaning f Article 19(5) f the Financial Services and Markets Act 2000 (Financial Prmtin) Order 2005 (the "Order"), and (c) high net wrth cmpanies, unincrprated assciatins and ther bdies t whm it may therwise lawfully be cmmunicated in accrdance with Article 49 f the Order (all such persns tgether being referred t as "relevant persns"). The securities are available nly t, and any invitatin, ffer r agreement t subscribe, purchase r therwise acquire such securities will be available nly t r will be engaged in nly with, relevant persns. Any persn wh is nt a relevant persn shuld nt act r rely n this cmmunicatin r any f its cntents , Mscw, Russia, Barabanniy per., 3, tel.: (+7495)